Skip to main content

Table 3 Farnesyl-transferase inhibitor in clinical trials

From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

inhibitors Other agents Disease Dosage Clinical trails No Pts Response Reference
Tipifarnib Bortezomib
1.0 mg/m2 		Elderly or relapsed AML 300-600 mg bid, ×21d Phase II 80 CR: 11% [30]
Tipifarnib +/- etoposide Elderly untreated AML   Phase II 107 Safe [31]
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us